论文部分内容阅读
【目的】测定基因重组乳链球菌防龋疫苗的免疫原性和免疫反应性。【方法】用基因重组乳链球菌 (HL 10 7)、乳链球菌 (LM 0 2 30 )、变形链球菌Ingbritt分别灌胃免疫实验动物BALB/c鼠 ,与未免疫组作对照 ,以酶联免疫吸附实验 (ELISA)测定血清及唾液中的抗变形链球菌表面蛋白PAc的特异性IgG和IgA。【结果】基因重组乳链球菌组血清中抗PAc IgG水平明显高于乳链球菌组 (P <0 0 1)、变形链球菌组 (P <0 0 5 )和未免疫组 (P <0 0 1) ,唾液中重组乳链球菌组抗PAc IgA抗体水平明显高于乳链球菌组 (P <0 0 1)和未免疫组 (P <0 0 1) ,与变形链球菌组无差别 (P >0 0 5 ) ,血清IgA和唾液IgG的水平在 4组中均无差别 (P >0 0 5 )。【结论】基因重组乳链球菌具有变形链球菌表面蛋白的免疫原性 ,能够在BALB/c鼠中产生特异性免疫反应
【Objective】 To determine the immunogenicity and immunoreactivity of genetically engineered Streptococcus agalactiae anti-caries vaccine. 【Method】 BALB / c mice were immunized intraperitoneally with genetically recombinant Streptococcus lactis (HL 10 7), Streptococcus lactis (LM 0 2 30) and Strebrtococcus mutans Ingbritt, respectively. Compared with the non-immunized group, Immunosorbent assay (ELISA) was used to measure specific IgG and IgA against Streptococcus mutans surface protein PAc in serum and saliva. 【Results】 The levels of anti-PAc IgG in the serum of recombinant Streptococcus agalactiae were significantly higher than those of Streptococcus lactis (P <0.01), Streptococcus mutans (P <0.05) and non-immunized groups (P <0 0) 1). The level of anti-PAc IgA antibody in salivary recombinant Lactococcus lactis was significantly higher than that in Streptococcus lactis (P <0.01) and non-immunized groups (P <0.01) > 0 0 5). There was no difference in serum IgA and salivary IgG between the 4 groups (P> 0.05). 【Conclusion】 The recombinant Lactococcus lactis has the immunogenicity of Streptococcus mutans surface protein and can produce specific immune response in BALB / c mice